• Antimicrobial Coatings Market Share, Size, Global Industry Analysis, Key Growth Drivers Trends, Segments, Opportunity and Forecast 2027
    The global antimicrobial coatings market size is predicted to reach USD 8,650.7 Million by 2027, exhibiting a CAGR of 11.5% during the forecast period. The rising awareness regarding the advantages of active ingredients found in antimicrobial coatings to prevent microbial growth in the wall, door handles and other indoor objects will accelerate the antimicrobial coatings market growth, states Fortune Business Insights in a report, titled Antimicrobial Coatings Market Size, Share & Industry Analysis, By Type (Metallic {Silver, Copper, and Others}, and Non-metallic {Polymeric, and Others}), By Application (Medical & Healthcare, Indoor Air / HVAC, Mold Remediation, Building & Construction, Food & Beverage, Textile, and Others), and Regional Forecast, 2020-2027” the market size stood at USD 3,690.0 Million in 2019. The rising prevalence of diseases will spur significant demand for antimicrobial coatings in prevention and protection against mold, fungi, and bacteria during the forecast period.

    Market Driver:

    Strong Utilization of Antimicrobial in Disease Prevention to Improve Business Prospects

    The increasing application of antimicrobial coatings in healthcare facilities can be a vital factor in inflating the demand of the market. For instance, Healthcare-related infections (HCAI), also known as nosocomial infections lead to a high rate of morbidity and mortality in patients. As per the World Health Organization, Fact Sheet, Hundreds of millions of patients are affected by healthcare-associated infections worldwide each year, leading to significant mortality and financial losses for health systems. The rising cases of HCAI in the developing nations will create opportunities for the market. The World Health Organization, states in high-income countries, approximately 30% of patients in intensive care units (ICU) are affected by at least one healthcare-associated infection. Likewise, the European Center for Disease Prevention and Control (ECDC) estimates that about 4.1 million acute care patients develop an HCAI annually, with 37,000 deaths directly attributed to HCAI. The increasing cognizance of HCAI and pandemics such as COVID-19 will lead to the improvement in the safety and hygiene of patients in hospitals, which, in turn, will aid the expansion of the market. Also, the rising concertation to prevent the growth of microbes, which can lead to infections or cause product degradation will foster healthy growth of the market.


    Regional Analysis:

    Favorable Laws and Policies will Strengthen Market in North America

    The market size in North America stood at USD 1,383.5 million in 2019. North America and is likely to remain dominant during the forecast period. The growth in the region is attributed to the rising demand for antimicrobial coatings in indoor air / HVAC and medical applications. Favorable Healthcare Policies and laws will further promote the market in North America. The rising demand from the food & beverages and apparel industry in the U.S. and Canada will support the growth in North America. The increasing living standards of people along with the rising healthcare spending in the U.S. will further aid the development of the market. The growing innovation in the healthcare industry and the growing production of processed foods will contribute positively to the market in North America.

    Significant Development:

    January 2019: Akzo Nobel N.V., a global leader and produced of powder coatings, announced that its Interpon AM range, containing BioCote antimicrobial protection was selected to be applied on 2,350 door handles in Abu Dhabi clinic. This coating combats the growth of microbes such as bacteria and mold.

    Information Source: -

    https://www.fortunebusinessinsights.com/antimicrobial-coatings-market-102784
    Antimicrobial Coatings Market Share, Size, Global Industry Analysis, Key Growth Drivers Trends, Segments, Opportunity and Forecast 2027 The global antimicrobial coatings market size is predicted to reach USD 8,650.7 Million by 2027, exhibiting a CAGR of 11.5% during the forecast period. The rising awareness regarding the advantages of active ingredients found in antimicrobial coatings to prevent microbial growth in the wall, door handles and other indoor objects will accelerate the antimicrobial coatings market growth, states Fortune Business Insights in a report, titled Antimicrobial Coatings Market Size, Share & Industry Analysis, By Type (Metallic {Silver, Copper, and Others}, and Non-metallic {Polymeric, and Others}), By Application (Medical & Healthcare, Indoor Air / HVAC, Mold Remediation, Building & Construction, Food & Beverage, Textile, and Others), and Regional Forecast, 2020-2027” the market size stood at USD 3,690.0 Million in 2019. The rising prevalence of diseases will spur significant demand for antimicrobial coatings in prevention and protection against mold, fungi, and bacteria during the forecast period. Market Driver: Strong Utilization of Antimicrobial in Disease Prevention to Improve Business Prospects The increasing application of antimicrobial coatings in healthcare facilities can be a vital factor in inflating the demand of the market. For instance, Healthcare-related infections (HCAI), also known as nosocomial infections lead to a high rate of morbidity and mortality in patients. As per the World Health Organization, Fact Sheet, Hundreds of millions of patients are affected by healthcare-associated infections worldwide each year, leading to significant mortality and financial losses for health systems. The rising cases of HCAI in the developing nations will create opportunities for the market. The World Health Organization, states in high-income countries, approximately 30% of patients in intensive care units (ICU) are affected by at least one healthcare-associated infection. Likewise, the European Center for Disease Prevention and Control (ECDC) estimates that about 4.1 million acute care patients develop an HCAI annually, with 37,000 deaths directly attributed to HCAI. The increasing cognizance of HCAI and pandemics such as COVID-19 will lead to the improvement in the safety and hygiene of patients in hospitals, which, in turn, will aid the expansion of the market. Also, the rising concertation to prevent the growth of microbes, which can lead to infections or cause product degradation will foster healthy growth of the market. Regional Analysis: Favorable Laws and Policies will Strengthen Market in North America The market size in North America stood at USD 1,383.5 million in 2019. North America and is likely to remain dominant during the forecast period. The growth in the region is attributed to the rising demand for antimicrobial coatings in indoor air / HVAC and medical applications. Favorable Healthcare Policies and laws will further promote the market in North America. The rising demand from the food & beverages and apparel industry in the U.S. and Canada will support the growth in North America. The increasing living standards of people along with the rising healthcare spending in the U.S. will further aid the development of the market. The growing innovation in the healthcare industry and the growing production of processed foods will contribute positively to the market in North America. Significant Development: January 2019: Akzo Nobel N.V., a global leader and produced of powder coatings, announced that its Interpon AM range, containing BioCote antimicrobial protection was selected to be applied on 2,350 door handles in Abu Dhabi clinic. This coating combats the growth of microbes such as bacteria and mold. Information Source: - https://www.fortunebusinessinsights.com/antimicrobial-coatings-market-102784
    Antimicrobial Coatings Market Size, Share | Global Report, 2027
    The global antimicrobial coatings market size was USD 3,690.0 million in 2019 and is projected to reach USD 8,650.7 Million by 2027, exhibiting a CAGR of 11.5% during the forecast period
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    0 Comments 0 Shares
  • Trainwreck (AUTO)
    United States
    Trainwreck is a vigorous plant that has incredible production. It has an extremely wide growth pattern which makes this strain ideal for the grower with height limitations. It has a huge production of lime green strong-smelling buds with incredible mold resistant and a low-maintenance plant structure. It gets its sweet turpentine smell from high levels of Terpinolene which has reported an anti-microbial and strong tranquilizing effect.

    Shop Now at: https://www.lbseedco.com/products/trainwreck-auto-fem
    Trainwreck is a vigorous plant that has incredible production. It has an extremely wide growth pattern which makes this strain ideal for the grower with height limitations. It has a huge production of lime green strong-smelling buds with incredible mold resistant and a low-maintenance plant structure. It gets its sweet turpentine smell from high levels of Terpinolene which has reported an anti-microbial and strong tranquilizing effect. Shop Now at: https://www.lbseedco.com/products/trainwreck-auto-fem
    Type
    New
    Price
    $100.00 (USD)
    Status
    In stock
    0 Comments 0 Shares
  • The microbial contract biomanufacturing market is projected to be worth USD 9.3 billion by 2030

    The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment

    For additional details, please visit
    https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
    The microbial contract biomanufacturing market is projected to be worth USD 9.3 billion by 2030 The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment For additional details, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
    Microbial Contract Biomanufacturing Market, 2020-2030 | Market Size | Industry Analysis | 2030
    The microbial contract biomanufacturing market report features an extensive study of the current market landscape and future opportunities...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • According to Fortune Business Insights The global biocides market share is expected to reach USD 9,914.2 million by 2028, exhibiting a CAGR of 4.2% between 2021 and 2028. The growing adoption of innovative solutions in the medical industry will contribute positively to the market growth during the forecast period, states Fortune Business Insights, in a report, titled “Biocides Market, 2021-2028” The market size stood at USD 7,195.1 million in 2020.

    Production in various sectors has been terminated due to the economic outage. This has resulted in a drop in sales volume and supply chain disruptions and a halt in paint & coatings shipments, considerably restricting this market. However, companies are introducing strategies to cope with the current situation, which, in turn, will incite the development of the global market in the forthcoming years.

    Acquisition of INTACE by LANXESS to Foster Growth

    LANXESS, a specialty chemicals firm, purchased INTACE SAS, a French firm, to expand its market share as one of the world's top producers of biocides and antimicrobials. The biocide firm, situated in Paris, makes specialist fungicides for the packaging sector. On January 14, 2021, LANXESS and the seller signed a memorandum of understanding to that effect. The parties have agreed to keep the acquisition price a secret. The acquisition is expected to close in the first quarter of 2021, according to LANXESS. The purchase will increase the biocides market share as INTACE anticipated revenue in half paid higher range by 2020. Paper, paperboard, soap packaging, labels, and banknotes are just a few of the applications for its goods. This business unit's products are utilized in a wide range of applications all around the world. The business unit delivers customer-specific solutions for diverse branches with its wide variety of active antibacterial agents and preservatives

    Increasing Product Demand in Medical Applications to Open Up New Possibilities

    The medical business is expanding as a result of increased consumer awareness of health and cleanliness, which is creating market possibilities. This, together with economic growth, is encouraging businesses to use new technology in developing medical solutions. Biocides are chemicals that are added to disinfectants and cleansers used in hospitals and clinics to keep them clean and sterilized. Surgical equipment, tools, surfaces, and fittings are all cleaned with them. The increase in demand can be ascribed to the product's ability to suppress microbial development. Furthermore, the product is used in the food and beverage industry and the leather industry. Thus, growing demand for these products will enable the speedy expansion of the market.

    Paints & Coatings to Hold the Lion’s Share

    Based on type, the market is segmented into halogen compounds, quaternary ammonium compounds, metallic compounds, phenolic, organic acids, organosulfur, and others.

    Based on applications, the market is categorized into water treatment, food and personal care products, cleaning products, furniture and furnishings, clothing and textiles, leather and suede, paints and coatings, fuel preservatives, and others. Paints & coatings are expected to account for the largest share during the forecast period. The growth is attributed to its high utilization in the construction and automotive industry.

    Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

    Thor Group Limited to Account for a High Share

    Thor Group Limited manufactures products for a wide range of industrial and consumer uses. To gain a competitive edge in the biocides market, leading manufacturers are employing techniques such as boosting brand recognition, growing regional presence, and launching new product offers. Companies are also investing in technology advancements in order to broaden their product offerings.

    The Report Lists the Key Companies in this Market:

    Vink Chemicals GmbH & Co. KG (Germany)
    Clariant (Switzerland)
    KemiraOyj (Finland)
    Troy Corporation (U.S.)
    Thor Group Limited (UK)
    Lanxess AG (Germany)
    Solvay SA (Belgium)
    Neogen Corporation (UK)
    Finoric LLC (U.S.)
    Shanghai ZhongxinYuxiang Chemical Co., Ltd (China)
    Shandong IRO Biocide Chemicals Co., Ltd. (China)
    Albemarle Corporation (U.S.)
    Lonza Group Ltd (Switzerland)
    Wuxi Honor Shine Chemical Co. Ltd. (China)


    Information Source:

    https://www.fortunebusinessinsights.com/biocides-market-105452
    According to Fortune Business Insights The global biocides market share is expected to reach USD 9,914.2 million by 2028, exhibiting a CAGR of 4.2% between 2021 and 2028. The growing adoption of innovative solutions in the medical industry will contribute positively to the market growth during the forecast period, states Fortune Business Insights, in a report, titled “Biocides Market, 2021-2028” The market size stood at USD 7,195.1 million in 2020. Production in various sectors has been terminated due to the economic outage. This has resulted in a drop in sales volume and supply chain disruptions and a halt in paint & coatings shipments, considerably restricting this market. However, companies are introducing strategies to cope with the current situation, which, in turn, will incite the development of the global market in the forthcoming years. Acquisition of INTACE by LANXESS to Foster Growth LANXESS, a specialty chemicals firm, purchased INTACE SAS, a French firm, to expand its market share as one of the world's top producers of biocides and antimicrobials. The biocide firm, situated in Paris, makes specialist fungicides for the packaging sector. On January 14, 2021, LANXESS and the seller signed a memorandum of understanding to that effect. The parties have agreed to keep the acquisition price a secret. The acquisition is expected to close in the first quarter of 2021, according to LANXESS. The purchase will increase the biocides market share as INTACE anticipated revenue in half paid higher range by 2020. Paper, paperboard, soap packaging, labels, and banknotes are just a few of the applications for its goods. This business unit's products are utilized in a wide range of applications all around the world. The business unit delivers customer-specific solutions for diverse branches with its wide variety of active antibacterial agents and preservatives Increasing Product Demand in Medical Applications to Open Up New Possibilities The medical business is expanding as a result of increased consumer awareness of health and cleanliness, which is creating market possibilities. This, together with economic growth, is encouraging businesses to use new technology in developing medical solutions. Biocides are chemicals that are added to disinfectants and cleansers used in hospitals and clinics to keep them clean and sterilized. Surgical equipment, tools, surfaces, and fittings are all cleaned with them. The increase in demand can be ascribed to the product's ability to suppress microbial development. Furthermore, the product is used in the food and beverage industry and the leather industry. Thus, growing demand for these products will enable the speedy expansion of the market. Paints & Coatings to Hold the Lion’s Share Based on type, the market is segmented into halogen compounds, quaternary ammonium compounds, metallic compounds, phenolic, organic acids, organosulfur, and others. Based on applications, the market is categorized into water treatment, food and personal care products, cleaning products, furniture and furnishings, clothing and textiles, leather and suede, paints and coatings, fuel preservatives, and others. Paints & coatings are expected to account for the largest share during the forecast period. The growth is attributed to its high utilization in the construction and automotive industry. Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Thor Group Limited to Account for a High Share Thor Group Limited manufactures products for a wide range of industrial and consumer uses. To gain a competitive edge in the biocides market, leading manufacturers are employing techniques such as boosting brand recognition, growing regional presence, and launching new product offers. Companies are also investing in technology advancements in order to broaden their product offerings. The Report Lists the Key Companies in this Market: Vink Chemicals GmbH & Co. KG (Germany) Clariant (Switzerland) KemiraOyj (Finland) Troy Corporation (U.S.) Thor Group Limited (UK) Lanxess AG (Germany) Solvay SA (Belgium) Neogen Corporation (UK) Finoric LLC (U.S.) Shanghai ZhongxinYuxiang Chemical Co., Ltd (China) Shandong IRO Biocide Chemicals Co., Ltd. (China) Albemarle Corporation (U.S.) Lonza Group Ltd (Switzerland) Wuxi Honor Shine Chemical Co. Ltd. (China) Information Source: https://www.fortunebusinessinsights.com/biocides-market-105452
    Biocides Market Size & Growth | Global Industry Forecast [2028]
    The biocides market is projected to grow from $7,419.8 million in 2021 to $9,914.2 million in 2028 at a CAGR of 4.2% in the forecast Period, 2021-2028
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    0 Comments 0 Shares
  • The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report

    Over the years, the rising popularity of biologics has led to a paradigm shift in healthcare. In the last decade alone, the annual number of approvals of biopharmaceuticals, by the US FDA, have steadily risen.

    To order this 750+ page report, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

    Key Inclusions
     A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
     Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.
     A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
     A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
     A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
     A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
     An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.
     A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.
     An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.
     A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).
     An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.
     A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
     A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
     Commonly Outsourced Business Operations
     Active Pharmaceutical Ingredients (API)
     Finished Dosage Formulations (FDF)
     Types of Expression System
     Mammalian
     Microbial
     Others
     Company Size
     Small
     Mid-Sized
     Large and Very Large
     Scale of Operation
     Preclinical
     Clinical
     Commercial
     Key Geographical Region
     North America
     Europe
     Asia-Pacific

    To request sample pages, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html

    Key Questions Answered
     Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?
     What is the global demand for biologics-based therapies?
     What are the major recent developments (such as partnerships and expansions) in this industry?
     What kind of partnership models are commonly adopted by stakeholders in this domain?
     What is the current, installed contract manufacturing capacity for biologics?
     How is the current and future market opportunity likely to be distributed across key market segments?


    For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html


    You may also be interested in the following titles:
    1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
    2. Antibody Contract Manufacturing Market, 2020-2030
    3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
    4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030




    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report Over the years, the rising popularity of biologics has led to a paradigm shift in healthcare. In the last decade alone, the annual number of approvals of biopharmaceuticals, by the US FDA, have steadily risen. To order this 750+ page report, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html Key Inclusions  A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.  Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.  A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.  A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.  A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.  A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.  An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.  An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.  A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).  An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.  A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:  Commonly Outsourced Business Operations  Active Pharmaceutical Ingredients (API)  Finished Dosage Formulations (FDF)  Types of Expression System  Mammalian  Microbial  Others  Company Size  Small  Mid-Sized  Large and Very Large  Scale of Operation  Preclinical  Clinical  Commercial  Key Geographical Region  North America  Europe  Asia-Pacific To request sample pages, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html Key Questions Answered  Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?  What is the global demand for biologics-based therapies?  What are the major recent developments (such as partnerships and expansions) in this industry?  What kind of partnership models are commonly adopted by stakeholders in this domain?  What is the current, installed contract manufacturing capacity for biologics?  How is the current and future market opportunity likely to be distributed across key market segments? For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html You may also be interested in the following titles: 1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030 2. Antibody Contract Manufacturing Market, 2020-2030 3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030 4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report features an extensive study on the contract service providers within the biopharmaceutical industry

    To order this 750+ page report, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

    Key Inclusions
     A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
     Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.
     A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
     A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
     A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
     A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
     An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.
     A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.
     An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.
     A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).
     An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.
     A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
     A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
     Commonly Outsourced Business Operations
     Active Pharmaceutical Ingredients (API)
     Finished Dosage Formulations (FDF)
     Types of Expression System
     Mammalian
     Microbial
     Others
     Company Size
     Small
     Mid-Sized
     Large and Very Large
     Scale of Operation
     Preclinical
     Clinical
     Commercial
     Key Geographical Region
     North America
     Europe
     Asia-Pacific

    To request sample pages, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html

    Key Questions Answered
     Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?
     What is the global demand for biologics-based therapies?
     What are the major recent developments (such as partnerships and expansions) in this industry?
     What kind of partnership models are commonly adopted by stakeholders in this domain?
     What is the current, installed contract manufacturing capacity for biologics?
     How is the current and future market opportunity likely to be distributed across key market segments?


    For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html


    You may also be interested in the following titles:
    1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
    2. Antibody Contract Manufacturing Market, 2020-2030
    3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
    4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030




    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report features an extensive study on the contract service providers within the biopharmaceutical industry To order this 750+ page report, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html Key Inclusions  A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.  Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.  A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.  A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.  A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.  A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.  An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.  An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.  A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).  An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.  A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:  Commonly Outsourced Business Operations  Active Pharmaceutical Ingredients (API)  Finished Dosage Formulations (FDF)  Types of Expression System  Mammalian  Microbial  Others  Company Size  Small  Mid-Sized  Large and Very Large  Scale of Operation  Preclinical  Clinical  Commercial  Key Geographical Region  North America  Europe  Asia-Pacific To request sample pages, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html Key Questions Answered  Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?  What is the global demand for biologics-based therapies?  What are the major recent developments (such as partnerships and expansions) in this industry?  What kind of partnership models are commonly adopted by stakeholders in this domain?  What is the current, installed contract manufacturing capacity for biologics?  How is the current and future market opportunity likely to be distributed across key market segments? For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html You may also be interested in the following titles: 1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030 2. Antibody Contract Manufacturing Market, 2020-2030 3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030 4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030 by Roots Analysis
    Driven by several blockbuster products, a burgeoning pipeline and the need for dedicated expertise in the myriad of technical nuances associated with biomolecules, the biopharmaceutical contract manufacturing market has a lucrative future

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030.”

    The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analyses, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and contract development and manufacturing organizations (CDMOs). Amongst other elements, the report includes:
     A detailed review of the overall landscape of companies offering biopharmaceutical contract manufacturing services.
     A detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions.
     Elaborate profiles of key players that claim to have a diverse range of capabilities related to the development, manufacturing and packaging of biologics.
     A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors.
     A case study on the growing global biosimilars market, highlighting the associated opportunities for biopharmaceutical CMOs and CDMOs.
     A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
     A detailed discussion on the overview, benefits and challenges associated with in-house manufacturing.
     A qualitative analysis, highlighting the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
     An analysis of the initiatives of big biopharma players engaged in this domain.
     An analysis of the recent collaborations, mergers and acquisitions and expansions that have been established in this domain, in the recent past.
     An analysis of the recent developments within the biopharmaceutical contract manufacturing industry.
     A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders engaged in this domain.
     An informed estimate of the annual demand for biologics based on several parameters.
     A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework.
     A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to biopharmaceutical developers.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Commonly outsourced business operations
     API
     FDF

    To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html



     Types of Expression Systems Used
     Mammalian
     Microbial
     Others

     Scale of Operation
     Preclinical / Clinical
     Commercial

     Company Size
     Small
     Mid-sized
     Large / Very Large

     Types of Biologics Manufactured
     Antibody Therapeutics
     Vaccines
     Cell Therapies
     Other Biologics

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific
     Latin America
     Middle East and North Africa

    To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html


    Key companies covered in the report
     AGC Biologics
     Boehringer Ingelheim
     Catalent
     Cytiva (GE Healthcare)
     FUJIFILM Diosynth Biotechnologies
     KBI Biopharma
     Kemwell Biopharma
     Lonza
     Luina Bio
     Novasep
     Olon
     Patheon
     Piramal Pharma Solutions
     Takara Bio
     WuXi AppTec (WuXi Biologics)

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030
    2. ADC Contract Manufacturing Market (4th Edition), 2020-2030
    3. Microbial Contract Manufacturing Market, 2020-2030
    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact Details
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com

    Roots Analysis
    Web: https://www.rootsanalysis.com/
    LinkedIn: https://in.linkedin.com/company/roots-analysis
    Twitter: https://twitter.com/RootsAnalysis.com
    Medium: https://medium.com/@RootsAnalysis
    Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora: https://rootsanalysisinsights.quora.com/
    Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030 by Roots Analysis Driven by several blockbuster products, a burgeoning pipeline and the need for dedicated expertise in the myriad of technical nuances associated with biomolecules, the biopharmaceutical contract manufacturing market has a lucrative future Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030.” The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analyses, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and contract development and manufacturing organizations (CDMOs). Amongst other elements, the report includes:  A detailed review of the overall landscape of companies offering biopharmaceutical contract manufacturing services.  A detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions.  Elaborate profiles of key players that claim to have a diverse range of capabilities related to the development, manufacturing and packaging of biologics.  A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors.  A case study on the growing global biosimilars market, highlighting the associated opportunities for biopharmaceutical CMOs and CDMOs.  A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes.  A detailed discussion on the overview, benefits and challenges associated with in-house manufacturing.  A qualitative analysis, highlighting the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.  An analysis of the initiatives of big biopharma players engaged in this domain.  An analysis of the recent collaborations, mergers and acquisitions and expansions that have been established in this domain, in the recent past.  An analysis of the recent developments within the biopharmaceutical contract manufacturing industry.  A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders engaged in this domain.  An informed estimate of the annual demand for biologics based on several parameters.  A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework.  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to biopharmaceutical developers.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Commonly outsourced business operations  API  FDF To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html  Types of Expression Systems Used  Mammalian  Microbial  Others  Scale of Operation  Preclinical / Clinical  Commercial  Company Size  Small  Mid-sized  Large / Very Large  Types of Biologics Manufactured  Antibody Therapeutics  Vaccines  Cell Therapies  Other Biologics  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html Key companies covered in the report  AGC Biologics  Boehringer Ingelheim  Catalent  Cytiva (GE Healthcare)  FUJIFILM Diosynth Biotechnologies  KBI Biopharma  Kemwell Biopharma  Lonza  Luina Bio  Novasep  Olon  Patheon  Piramal Pharma Solutions  Takara Bio  WuXi AppTec (WuXi Biologics) For additional details, please visit https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030 2. ADC Contract Manufacturing Market (4th Edition), 2020-2030 3. Microbial Contract Manufacturing Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
    Biopharmaceutical Contract Manufacturing Market (4th Edition) | Industry Analysis | Market Size | 2030
    With a current capacity utilization of ~70%, the biopharma contract manufacturing (CMO) market is equiped to handle the growing demand for biologics
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • Antimicrobial Susceptibility Testing Market is expected to value over USD 4.6 billion by 2028 end with a CAGR of over 5.4% during the forecast period 2021 to 2028. As per the analysis done by analysts, the Antimicrobial Susceptibility Testing Market is anticipated to attain substantial growth over the forecast period. The report explains that the market is expected to register a remarkable rate of growth by the forecast period.

    To Know More - https://www.futurewiseresearch.com/healthcare-market-research/Antimicrobial-Susceptibility-Testing/7885
    Antimicrobial Susceptibility Testing Market is expected to value over USD 4.6 billion by 2028 end with a CAGR of over 5.4% during the forecast period 2021 to 2028. As per the analysis done by analysts, the Antimicrobial Susceptibility Testing Market is anticipated to attain substantial growth over the forecast period. The report explains that the market is expected to register a remarkable rate of growth by the forecast period. To Know More - https://www.futurewiseresearch.com/healthcare-market-research/Antimicrobial-Susceptibility-Testing/7885
    0 Comments 0 Shares

  • The global Digestive enzyme market size is expected to reach USD 1,319.8 Million by 2028 at a CAGR of 10.3%, according to a new report by Reports and Data. This can be mainly associated with the rise in awareness of gastrointestinal disorders, muscle improvement and fat reduction supplements. The demand of the market for digestive enzymes is driven by the rising disposable income and changing lifestyles of people around the globe leading to the consequent shift away from healthy diets.
    Digestive enzymes are substances that are used to add nutrients to the diet or to lower the risks of health problems, like indigestion, chronic pancreatitis, irritable bowel syndrome, muscle improvement and obesity. The dosage form of digestive enzymes might be in the form of pills, capsules, powders, extracts, or liquids, containing Proteases, Lipases and Amylases.
    Growing competition in the market has influenced the established players to invest massively in R&D to come up with better products in order to lure and retain their consumers. They are also starting to adopt various strategies like partnerships with retail chain companies to improve their global sales.
    Get a sample of the report @ https://reportsanddata.com/sample-enquiry-form/1251
    The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances.
    Key players in the market include
    Country Life LLC., National Enzyme Company, Rainbow Light Nutritional Systems Inc., Garden Of Life Inc., Biotics Research Corporation, Food State Inc., Matsun Nutrition, Metagenics, Inc., Twinlab Corporation, and Abbott Nutrition, among others.
    Furthermore, the report segments Digestive Enzymes market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period.
    Dosage form Outlook (Volume, Kilo tons; 2018-2026 and Revenue, USD Million; 2018-2028)
    • Tablets
    • Capsules
    • Powder
    • Liquids
    • Others
    Product type Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Million; 2018-2028)
    • Carbohydrates
    • Protease
    • Lipase
    • Others
    Origin Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Million; 2018-2028)
    • Animal
    • Fungi
    • Microbial
    • Plant
    Application Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Million; 2018-2028)
    • Infant Nutrition
    • Medical Nutrition
    • Sports Nutrition
    • Other End uses
    For a better understanding of the global Digestive Enzymes market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread across key geographical regions such as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is analysed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market. It provides insights into production and consumption patterns, supply and demand ratio, export/import, current and emerging trends and demands, market share, market size, revenue contribution, and presence of key players in each region.
    Request a discount on the report @ https://reportsanddata.com/discount-enquiry-form/1251
    In-depth regional analysis includes:
    • North America (U.S., Canada, Mexico)
    • Europe (Italy, U.K., Germany, France, Rest of EU)
    • Asia Pacific (India, China, Japan, South Korea, Australia, Rest of APAC)
    • Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America)
    • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
    To know more about the report @ https://reportsanddata.com/report-detail/digestive-enzyme-market
    Benefits of the Global Digestive Enzymes Report:
    • Comprehensive analysis of the opportunities and risks of the Digestive Enzymes market
    • Detailed study of the latest product and technological developments and innovations of the Digestive Enzymes market
    • Business strategies and plans are analysed for understanding the Digestive Enzymes market scenario
    • Revenue forecast of Digestive Enzymes market for the forecast period 2020-2028
    • Comprehensive analysis of the drivers, constraints, limitations, challenges, and opportunities
    • Latest and emerging market trends analysis and their impact on product and application demand
    • Study of recent M&A, joint ventures, collaborations, partnerships, product launches and brand promotions among others
    • Extensive SWOT analysis and Porter’s Five Forces analysis along with investment return analysis and feasibility
    Request a customization of the report @ https://reportsanddata.com/request-customization-form/1251
    Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements.
    Browse More Reports :

    Pet Insurance Market Size
    Virtual Reality in Healthcare Market Trends


    About Reports and Data
    Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
    Contact Us:
    John W
    Head of Business Development
    Reports and Data | Web: www.reportsanddata.com
    Direct Line: +1-212-710-1370
    E-mail: sales@reportsanddata.com

    The global Digestive enzyme market size is expected to reach USD 1,319.8 Million by 2028 at a CAGR of 10.3%, according to a new report by Reports and Data. This can be mainly associated with the rise in awareness of gastrointestinal disorders, muscle improvement and fat reduction supplements. The demand of the market for digestive enzymes is driven by the rising disposable income and changing lifestyles of people around the globe leading to the consequent shift away from healthy diets. Digestive enzymes are substances that are used to add nutrients to the diet or to lower the risks of health problems, like indigestion, chronic pancreatitis, irritable bowel syndrome, muscle improvement and obesity. The dosage form of digestive enzymes might be in the form of pills, capsules, powders, extracts, or liquids, containing Proteases, Lipases and Amylases. Growing competition in the market has influenced the established players to invest massively in R&D to come up with better products in order to lure and retain their consumers. They are also starting to adopt various strategies like partnerships with retail chain companies to improve their global sales. Get a sample of the report @ https://reportsanddata.com/sample-enquiry-form/1251 The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances. Key players in the market include Country Life LLC., National Enzyme Company, Rainbow Light Nutritional Systems Inc., Garden Of Life Inc., Biotics Research Corporation, Food State Inc., Matsun Nutrition, Metagenics, Inc., Twinlab Corporation, and Abbott Nutrition, among others. Furthermore, the report segments Digestive Enzymes market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period. Dosage form Outlook (Volume, Kilo tons; 2018-2026 and Revenue, USD Million; 2018-2028) • Tablets • Capsules • Powder • Liquids • Others Product type Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Million; 2018-2028) • Carbohydrates • Protease • Lipase • Others Origin Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Million; 2018-2028) • Animal • Fungi • Microbial • Plant Application Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Million; 2018-2028) • Infant Nutrition • Medical Nutrition • Sports Nutrition • Other End uses For a better understanding of the global Digestive Enzymes market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread across key geographical regions such as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is analysed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market. It provides insights into production and consumption patterns, supply and demand ratio, export/import, current and emerging trends and demands, market share, market size, revenue contribution, and presence of key players in each region. Request a discount on the report @ https://reportsanddata.com/discount-enquiry-form/1251 In-depth regional analysis includes: • North America (U.S., Canada, Mexico) • Europe (Italy, U.K., Germany, France, Rest of EU) • Asia Pacific (India, China, Japan, South Korea, Australia, Rest of APAC) • Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America) • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA) To know more about the report @ https://reportsanddata.com/report-detail/digestive-enzyme-market Benefits of the Global Digestive Enzymes Report: • Comprehensive analysis of the opportunities and risks of the Digestive Enzymes market • Detailed study of the latest product and technological developments and innovations of the Digestive Enzymes market • Business strategies and plans are analysed for understanding the Digestive Enzymes market scenario • Revenue forecast of Digestive Enzymes market for the forecast period 2020-2028 • Comprehensive analysis of the drivers, constraints, limitations, challenges, and opportunities • Latest and emerging market trends analysis and their impact on product and application demand • Study of recent M&A, joint ventures, collaborations, partnerships, product launches and brand promotions among others • Extensive SWOT analysis and Porter’s Five Forces analysis along with investment return analysis and feasibility Request a customization of the report @ https://reportsanddata.com/request-customization-form/1251 Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements. Browse More Reports : Pet Insurance Market Size Virtual Reality in Healthcare Market Trends About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John W Head of Business Development Reports and Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com
    Digestive Enzymes Market Growth, Trends and Forecast, 2021-2028
    Digestive enzymes market is expected to register a CAGR of 10.3%, key factors as growing geriatric population, increasing incidences of gastrointestinal diseases including irritable bowel syndrome, inflammatory bowel disease, constipation, & rising consumer awareness about the gut health benefits of digestive enzymes
    REPORTSANDDATA.COM
    0 Comments 0 Shares

  • According to the current analysis of Reports and Data, The global Immunohistochemistry market was valued at USD 1,736.4 million in 2018 and is expected to reach USD 3,359.8 million by the year 2026, growing at a CAGR of 8.6%.
    Immunohistochemistry (IHC) has crucial applications in the field of tissue distribution of antigens by using monoclonal and polyclonal antibodies. It is used for cancer diagnosis, because it determines the presence of tumor antigens. It is a technique which combines immunological, anatomical, and biochemical processes to identify tissue components by the interaction of target antigens with specific antibodies that are tagged by a label. Immunohistochemistry used by public and private organizations to check localization and distribution of cellular components within the cells.
    Immunohistochemistry is being applied in many other areas. Immunohistochemistry is widely used to predict therapeutic response in two important tumors, i.e. carcinoma of breast and prostate. Both these tumors are under the growth regulation of the hormones estrogen and androgen, respectively. The specific receptors for these growth regulating hormones are located on respective tumor cells. Tumors expressing high level of receptor positivity would respond favorably to removal of the endogenous source of such hormones or hormonal therapy is administered to lower their levels – estrogen therapy in prostate cancer and androgen therapy in breast cancer. Immunohistochemistry techniques are also being applied to confirm infectious agent in tissues by use of specific antibodies against microbial DNA or RNA, e.g. in Cytomegalo virus, Hepatitis B virus, Hepatitis C virus, etc. The application is used routinely in validation of disease targets as it allows visualizing expression of the target in the affected tissue during the disease process. Another important advantage of Immunohistochemistry is that it can also be used to detect organisms in cytological preparations such as fluids, sputum samples, and material obtained from fine needle aspiration procedures. This can be very helpful in certain situations such as detection of pneumocystis from the sputum of an immunocompromised patient who needs rapid and precise confirmation of infection in order to begin immediate and appropriate therapy.
    Specific diagnosis of muscular dystrophy is important because of the genetic counseling implications of inherited disease and accurate prognostication. In recent years, abnormalities in several muscle proteins have been identified in muscular dystrophies. Such abnormalities involve proteins located in the sarcolemma, extracellular matrix, cytosol, nucleus, and other sites within muscle fibers. Skeletal muscle biopsy can play a main role in differentiating vascular dystrophy from non-dystrophic disorders and Immunohistochemistry can assist in establishing a specific diagnosis of the dystrophies for which specific protein abnormalities are known. In the last few years, immunohistochemical staining for beta amyloid precursor protein has been validated as a method to detect axonal injury within as little as 2–3 h of head injury. Immunohistochemical detection of axonal injury can be useful in establishing timing of a traumatic insult in medico-legal settings.
    Rapid growth of healthcare investment in emerging economies and technological development in invitro industry creates the opportunities to manufacturers for Immunohistochemistry kit, equipment and reagents. Growing prevalence of chronic diseases including cancer, cardiovascular diseases, infectious diseases, autoimmune diseases, diabetes mellitus, and nephrological diseases are the key factors for the growth of the market. Significant rise in R&D spending and shift towards comprehensive healthcare solutions are impelling the market growth.
    Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2198
    The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances.
    Key players in the market include
    Abcam plc; Agilent Technologies; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Danaher Corporation; Merck KGaA; PerkinElmer, Inc.; and Thermo Fisher Scientific, Inc.
    For a better understanding of the global Immunohistochemistry market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread across key geographical regions such as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is analysed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market. It provides insights into production and consumption patterns, supply and demand ratio, export/import, current and emerging trends and demands, market share, market size, revenue contribution, and presence of key players in each region.
    Furthermore, the report segments Immunohistochemistry market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period.
    Type (Revenue, USD Million; 2017–2027)
    • Antibodies
    o Primary Antibodies
    o Secondary Antibodies
    • Equipment
    o Slide Staining Systems
    o Tissue Microarrays
    o Tissue Processing Systems
    o Slide Scanners
    o Others
    • Reagents
    o Histological Stains
    o Blocking Sera and Reagents
    o Chromogenic Substrates
    o Fixation Reagents
    o Stabilizers
    o Organic Solvents
    o Proteolytic Enzymes
    o Diluents
    • Kits

    Application (Revenue, USD Million; 2017–2027)
    • Diagnostics
    o Cancer
    o Infectious Diseases
    o Cardiovascular Diseases
    o Autoimmune Diseases
    o Diabetes Mellitus
    o Nephrological Diseases
    • Drug Testing

    End Use (Revenue, USD Million; 2017–2027)
    • Hospitals and Diagnostic Laboratories
    • Clinics
    • Research Institutes
    • Others

    Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2198
    In-depth regional analysis includes:
    • North America (U.S., Canada, Mexico)
    • Europe (Italy, U.K., Germany, France, Rest of EU)
    • Asia Pacific (India, China, Japan, South Korea, Australia, Rest of APAC)
    • Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America)
    • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
    To know more about the report @ https://www.reportsanddata.com/report-detail/immunohistochemistry-market
    Benefits of the Global Immunohistochemistry Report:
    • Comprehensive analysis of the opportunities and risks of the Immunohistochemistry market
    • Detailed study of the latest product and technological developments and innovations of the Immunohistochemistry market
    • Business strategies and plans are analysed for understanding the Immunohistochemistry market scenario
    • Revenue forecast of Immunohistochemistry market for the forecast period 2020-2027
    • Comprehensive analysis of the drivers, constraints, limitations, challenges, and opportunities
    • Latest and emerging market trends analysis and their impact on product and application demand
    • Study of recent M&A, joint ventures, collaborations, partnerships, product launches and brand promotions among others
    • Extensive SWOT analysis and Porter’s Five Forces analysis along with investment return analysis and feasibility
    Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2198
    Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements.
    Browse More Reports :
    ENT Medical Devices Market Report
    Cryptococcosis Market Research

    About Reports and Data
    Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
    Contact Us:
    John W
    Head of Business Development
    Reports and Data | Web: www.reportsanddata.com
    Direct Line: +1-212-710-1370
    E-mail: sales@reportsanddata.com
    According to the current analysis of Reports and Data, The global Immunohistochemistry market was valued at USD 1,736.4 million in 2018 and is expected to reach USD 3,359.8 million by the year 2026, growing at a CAGR of 8.6%. Immunohistochemistry (IHC) has crucial applications in the field of tissue distribution of antigens by using monoclonal and polyclonal antibodies. It is used for cancer diagnosis, because it determines the presence of tumor antigens. It is a technique which combines immunological, anatomical, and biochemical processes to identify tissue components by the interaction of target antigens with specific antibodies that are tagged by a label. Immunohistochemistry used by public and private organizations to check localization and distribution of cellular components within the cells. Immunohistochemistry is being applied in many other areas. Immunohistochemistry is widely used to predict therapeutic response in two important tumors, i.e. carcinoma of breast and prostate. Both these tumors are under the growth regulation of the hormones estrogen and androgen, respectively. The specific receptors for these growth regulating hormones are located on respective tumor cells. Tumors expressing high level of receptor positivity would respond favorably to removal of the endogenous source of such hormones or hormonal therapy is administered to lower their levels – estrogen therapy in prostate cancer and androgen therapy in breast cancer. Immunohistochemistry techniques are also being applied to confirm infectious agent in tissues by use of specific antibodies against microbial DNA or RNA, e.g. in Cytomegalo virus, Hepatitis B virus, Hepatitis C virus, etc. The application is used routinely in validation of disease targets as it allows visualizing expression of the target in the affected tissue during the disease process. Another important advantage of Immunohistochemistry is that it can also be used to detect organisms in cytological preparations such as fluids, sputum samples, and material obtained from fine needle aspiration procedures. This can be very helpful in certain situations such as detection of pneumocystis from the sputum of an immunocompromised patient who needs rapid and precise confirmation of infection in order to begin immediate and appropriate therapy. Specific diagnosis of muscular dystrophy is important because of the genetic counseling implications of inherited disease and accurate prognostication. In recent years, abnormalities in several muscle proteins have been identified in muscular dystrophies. Such abnormalities involve proteins located in the sarcolemma, extracellular matrix, cytosol, nucleus, and other sites within muscle fibers. Skeletal muscle biopsy can play a main role in differentiating vascular dystrophy from non-dystrophic disorders and Immunohistochemistry can assist in establishing a specific diagnosis of the dystrophies for which specific protein abnormalities are known. In the last few years, immunohistochemical staining for beta amyloid precursor protein has been validated as a method to detect axonal injury within as little as 2–3 h of head injury. Immunohistochemical detection of axonal injury can be useful in establishing timing of a traumatic insult in medico-legal settings. Rapid growth of healthcare investment in emerging economies and technological development in invitro industry creates the opportunities to manufacturers for Immunohistochemistry kit, equipment and reagents. Growing prevalence of chronic diseases including cancer, cardiovascular diseases, infectious diseases, autoimmune diseases, diabetes mellitus, and nephrological diseases are the key factors for the growth of the market. Significant rise in R&D spending and shift towards comprehensive healthcare solutions are impelling the market growth. Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2198 The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances. Key players in the market include Abcam plc; Agilent Technologies; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Danaher Corporation; Merck KGaA; PerkinElmer, Inc.; and Thermo Fisher Scientific, Inc. For a better understanding of the global Immunohistochemistry market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread across key geographical regions such as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is analysed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market. It provides insights into production and consumption patterns, supply and demand ratio, export/import, current and emerging trends and demands, market share, market size, revenue contribution, and presence of key players in each region. Furthermore, the report segments Immunohistochemistry market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period. Type (Revenue, USD Million; 2017–2027) • Antibodies o Primary Antibodies o Secondary Antibodies • Equipment o Slide Staining Systems o Tissue Microarrays o Tissue Processing Systems o Slide Scanners o Others • Reagents o Histological Stains o Blocking Sera and Reagents o Chromogenic Substrates o Fixation Reagents o Stabilizers o Organic Solvents o Proteolytic Enzymes o Diluents • Kits Application (Revenue, USD Million; 2017–2027) • Diagnostics o Cancer o Infectious Diseases o Cardiovascular Diseases o Autoimmune Diseases o Diabetes Mellitus o Nephrological Diseases • Drug Testing End Use (Revenue, USD Million; 2017–2027) • Hospitals and Diagnostic Laboratories • Clinics • Research Institutes • Others Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2198 In-depth regional analysis includes: • North America (U.S., Canada, Mexico) • Europe (Italy, U.K., Germany, France, Rest of EU) • Asia Pacific (India, China, Japan, South Korea, Australia, Rest of APAC) • Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America) • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA) To know more about the report @ https://www.reportsanddata.com/report-detail/immunohistochemistry-market Benefits of the Global Immunohistochemistry Report: • Comprehensive analysis of the opportunities and risks of the Immunohistochemistry market • Detailed study of the latest product and technological developments and innovations of the Immunohistochemistry market • Business strategies and plans are analysed for understanding the Immunohistochemistry market scenario • Revenue forecast of Immunohistochemistry market for the forecast period 2020-2027 • Comprehensive analysis of the drivers, constraints, limitations, challenges, and opportunities • Latest and emerging market trends analysis and their impact on product and application demand • Study of recent M&A, joint ventures, collaborations, partnerships, product launches and brand promotions among others • Extensive SWOT analysis and Porter’s Five Forces analysis along with investment return analysis and feasibility Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2198 Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements. Browse More Reports : ENT Medical Devices Market Report Cryptococcosis Market Research About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John W Head of Business Development Reports and Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com
    Immunohistochemistry Market | Size, Share | Global Report
    Immunohistochemistry market size is projected to reach USD 3.64 billion by 2027 registering a CAGR of 8.6%. The expanding demand for targeted immunotherapy & biologic therapy for anticancer drug development and increasing FDA approvals are expected to boost the market growth.
    WWW.REPORTSANDDATA.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

Sponsored